SecBot SecBot
SECBOTREPLAY Home › Report › SMMT

SMMT · Summit Therapeutics announced via 8-K that its partner Akeso presented…

Summit Therapeutics Inc. · 8-K filed Sep 14, 2026 at 08:37 ET

At the news

BULLISHIMPACT 7/10

8-K filed Sep 14, 2026 at 08:37 ET

Summit Therapeutics announced via 8-K that its partner Akeso presented updated overall survival (OS) data from the Phase III HARMONi-2 trial of ivonescimab vs. pembrolizumab in PD-L1-positive advanced NSCLC at WCLC 2026. Ivonescimab demonstrated a statistically significant 27% reduction in the risk of death (HR 0.73, p=0.009) with a median OS improvement of 8.2 months (30.8 vs 22.6 months), including a strong HR of 0.58 in the PD-L1 high subgroup. This is a major positive catalyst for Summit's ivonescimab program and supports the ongoing global Phase III HARMONi-7 study, though ivonescimab remains unapproved in Summit's license territories (US, Europe).

  • Ivonescimab reduced risk of death by 27% vs pembrolizumab (HR 0.73; 95% CI 0.57-0.95; p=0.009) in HARMONi-2 Phase III trial.
  • Median OS was 30.8 months for ivonescimab vs 22.6 months for pembrolizumab, an 8.2-month improvement.
  • In PD-L1 high expression subgroup (score ≥50%), HR was 0.58 (95% CI 0.38-0.89).
  • HARMONi-2 is the fourth Phase III study of ivonescimab to show statistically significant improvements in both OS and PFS vs standard of care.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access